

Interview Summary

Application No.
08/704,445

Applicant(s)
Chen et al.

Examiner
Karen M. Hauda

Group Art Unit
1632



All participants (applicant, applicant's representative, PTO personnel):

(1) Karen M. Hauda

(3) Antoinette Konski

(2) Paula Borden

(4) _____

Date of Interview Jul 27, 1998

Type: ☒ Telephonic ☐ Personal (copy is given to ☐ applicant ☐ applicant's representative).

Exhibit shown or demonstration conducted: ☒ Yes ☐ No. If yes, brief description:

See attached

Agreement ☐ was reached. ☒ was not reached.

Claim(s) discussed: All in general.

Identification of prior art discussed:

Description of the general nature of what was agreed to if an agreement was reached, or any other comments:

The Examiner and applicants discussed claim amendments to potentially place the claims in condition for allowance.
Applicants indicated they wanted an action on the merits regarding the issues discussed.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1. ☐ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2. ☐ Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.

Examiner Note: You must sign and stamp this form unless it is an attachment to a signed Office action.

MORRISON & FOERSTER LLP

Attorneys at Law
 755 Page Mill Road
 Palo Alto, California 94304-1018
 Telephone: (650) 813-5600
 Facsimile: (650) 494-0792

98 JUL 23 10:40

(703)-305-7230

To: Examiner Karen Houda

Facsimile: 703-308-8724

U.S. PTO G.A.U. 1632

Phone: 703-305-6608

To:

Morrison & Foerster Office:

- | | | | | |
|------------------------------------|--------------------------------------|--|--|---|
| <input type="checkbox"/> Brussels | <input type="checkbox"/> London | <input type="checkbox"/> Orange County | <input type="checkbox"/> San Francisco | <input type="checkbox"/> Walnut Creek |
| <input type="checkbox"/> Denver | <input type="checkbox"/> Los Angeles | <input type="checkbox"/> Palo Alto | <input type="checkbox"/> Singapore | <input type="checkbox"/> Washington, D.C. |
| <input type="checkbox"/> Hong Kong | <input type="checkbox"/> New York | <input type="checkbox"/> Sacramento | <input type="checkbox"/> Tokyo | |

From: Paula A. Borden

Date: July 23, 1998

We are transmitting a total of 6 pages (including this page).

Original or hard copy to follow if this box is checked ☐.

If you do not receive all pages, please call as soon as possible (650) 813-5776

Preparer of this slip has confirmed that facsimile number given is correct: 4549, PAB2

This facsimile contains confidential information which may also be privileged. Unless you are the addressee (or authorized to receive for the addressee), you may not copy, use, or distribute it. If you have received it in error, please advise Morrison & Foerster immediately by telephone or facsimile and return it promptly by mail.

Comments:

Claims for discussion on July 27, 1998 at
 10:00 a.m. EST.

Morrison & Foerster docket No. 20296-20013.01

**METHOD OF PREVENTING DEPLETION OF NON-AUTOLOGOUS
HEMATOPOIETIC
CELLS AND ANIMAL MODEL SYSTEM FOR USE THEREOF**

**U.S. Serial No. 08/704,445
Attorney Docket No.: 20296-20013.01**

DRAFT

PROPOSED CLAIM AMENDMENTS

(July 22, 1998; to be submitted to Examiner July 23, 1998)

1. (Amended) A method of reducing [preventing] depletion in an animal of non-autologous hematopoietic cells comprising [decreasing] administering to the animal an effective amount of an agent which decreases the number of endogenous macrophages to a level effective to [substantially prevent] reduce depletion of the non-autologous hematopoietic cells.
2. The method according to claim 1 wherein the non-autologous hematopoietic cells are injected into the animal.
3. The method according to claim 1 wherein the cells are made by hematopoietic tissue engrafted into the animal.
4. (Cancelled) The method according to claim 1 wherein the macrophages are decreased by administering to the animal an effective amount of an agent which decreases the level of endogenous macrophages.
5. The method according to claim [4] 1 wherein the agent is liposome-encapsulated dichloromethylenc diphosphonate.
6. (Cancelled) The method according to claim 1 wherein the macrophages are decreased genetically.
7. The method according to claim 1 wherein the animal is immunocompromised.

DRAFT

8. The method according to claim 7 wherein the animal is immunocompromised due to infection with an immunodeficiency virus.

9. The method according to claim 8 wherein the animal is human and the virus is human immunodeficiency virus.

10. The method according to claim 7 wherein the animal is immunocompromised due to radiation therapy.

11. The method according to claim 7 wherein the animal is immunocompromised due to chemotherapy.

12. The method according to claim 7 wherein the animal is selected from the group consisting humans, mice, scid/scid mice, SCID-hu mice, and CID horses.

13. The method according to claim 12 wherein the animal is a SCID-hu Thy/Liv mouse.

14. The method according to claim 7 wherein the animal is transplanted with non-autologous hematopoietic tissue.

15. The method according to claim 7 wherein the non-autologous hematopoietic cells are injected into the animal.

16. The method according to claim 7 wherein the agent is liposome-encapsulated dichloromethylene diphosphonate.

17. The method according to claim 15 wherein the animal is a human and the non-autologous hematopoietic cells are injected.

DRAFT

18. (Amended) A method of treating an immunocompromised animal comprising administering to the animal an effective amount of non-autologous hematopoietic cells and [decreasing] administering to the animal an effective amount of an agent which decreases the number of endogenous macrophages to a level sufficient to reduce [prevent substantial] depletion of the non-autologous hematopoietic cells.

19. (Amended) A non-human mammal comprising human hematopoietic cells wherein the mammal contains a decreased level of endogenous macrophages sufficient to reduce [prevent substantial] depletion of non-autologous hematopoietic cells, wherein the decreased level of endogenous macrophages is achieved by administering to the mammal an effective amount of an agent which decreases the number of endogenous macrophages.

20. The non-human mammal according to claim 19 wherein the mammal is immunocompromised.

21. The non-human mammal according to claim 19 wherein the mammal contains engrafted human hematopoietic tissue.

22. The non-human mammal according to claim 19 wherein the non-autologous hematopoietic cells are produced by the engrafted tissue.

23. The mammal according to claim 19 wherein the mammal is selected from the group consisting of SCID/SCID mice, SCID-hu Thy/Liv mice and CID horses.

24. (Amended) A method of restoring hematopoietic cells to an immunocompromised human comprising the steps of administering an effective amount of human peripheral blood cells in conjunction with [decreasing] administering to the human an effective amount of an agent which decreases the number of endogenous macrophages.

DRAFT

25. The method according to claim 24 wherein the immunocompromised human is infected with human immunodeficiency virus.

26. The method according to claim 25 wherein the peripheral blood cells are hematolymphoid.

27. The method according to claim 26 wherein the blood cells are T cells.

28. The method according to claim 26 wherein the blood cells are CD4⁺ T cells.

29. The method according to claim 25 wherein the peripheral blood cells are administered by direct injection into the blood stream of the human.

30. The method according to claim 25 wherein the peripheral blood cells are administered by bone marrow transplantation of hematopoietic stem cells into the human.

31. (Twice Amended) A method of improving engraftment efficiency for transplantation of a population of non-autologous hematopoietic stem cells in a host animal having an endogenous hematopoietic stem cell population, comprising the steps of ablating the endogenous hematopoietic stem cell population of the host animal and transplanting the non-autologous hematopoietic stem cells into the host animal in conjunction with [decreasing] administering to the animal an effective amount of an agent which decreases the number of endogenous macrophages in the host animal.

32. (New) A method according to claim 18, wherein the agent is liposome-encapsulated dichloromethylene diphosphonate.

33. (New) A method according to claim 19, wherein the agent is liposome-encapsulated dichloromethylene diphosphonate.

DRAFT

34. (New) A method according to claim 24, wherein the agent is liposome-encapsulated dichloromethylene diphosphonate.

35. (New) A method according to claim 31, wherein the agent is liposome-encapsulated dichloromethylene diphosphonate.